On a disclosed annual basis, revenue rose from KRW 39.8 billion in 2022 to KRW 42.6 billion in 2023 (up 7.2%) and then to KRW 58.8 billion in 2024 (up 37.8%), the largest year in the 2022 to 2025 span. Revenue then fell 10.7% to KRW 52.5 billion in 2025.
Operating results moved from an operating loss of KRW 3.8 billion in 2022 and KRW 6.27 billion in 2023 to operating profit of KRW 6.19 billion in 2024, a swing to profit.
Operating profit then dropped 68.3% to KRW 1.96 billion in 2025, and the operating margin went from -9.6% and -14.7% in 2022 and 2023 to 10.5% in 2024 and 3.7% in 2025. Net income attributable to controlling shareholders turned from a KRW 13.1 billion profit in 2024 to a KRW 7.21 billion loss in 2025.
Net income including non-controlling interests moved from KRW 14.7 billion in 2024 to a KRW 8.03 billion net loss in 2025.
Reporting on the 2025 year-end settlement cited a convertible bond derivative valuation loss of about KRW 6.45 billion and human drug development costs of about KRW 6.12 billion, both of which sit outside the sales line. Operating cash flow was KRW 8.85 billion in 2024 and -KRW 622 million in 2025.
Quarterly, Q3 2025 revenue was KRW 12.5 billion with operating profit of KRW 6.572 million, while Q4 2025 revenue of KRW 11.9 billion (down 4.7% from the prior quarter) came with an operating loss of KRW 241 million.
Q1 2026 posted revenue of KRW 11.9 billion, operating profit of KRW 301 million and net income attributable to controlling shareholders of KRW 857 million. Q2 2026 revenue rose to KRW 16.7 billion (up 39.9%) with operating profit of KRW 1.64 billion.
Q3 2026 revenue fell 27.4% to KRW 12.1 billion, and the company booked an operating loss of KRW 1.27 billion and a net loss attributable to controlling shareholders of KRW 4.31 billion, a wider loss than a year earlier. The last four quarters total KRW 6.75 billion in such losses.